Skip to main content

Journal of Cancer Research and Clinical Oncology

Ausgabe 3/2014

Inhalt (19 Artikel)

Review

Perspectives in anaesthesia for cancer surgery

Patrice Forget, Marc De Kock

Open Access Original Paper

Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer

Sebastian Szubert, Dariusz Szpurek, Rafal Moszynski, Michal Nowicki, Andrzej Frankowski, Stefan Sajdak, Slawomir Michalak

Original Paper

Effects of resveratrol on oral squamous cell carcinoma (OSCC) cells in vitro

Zhou Shan, Guo Yang, Wang Xiang, Wang Pei-jun, Zhang Bin

Original Paper

Thromboxane A2 exerts promoting effects on cell proliferation through mediating cyclooxygenase-2 signal in lung adenocarcinoma cells

Run-Yue Huang, Shan-Shan Li, Hui-Zhen Guo, Yu Huang, Xian Zhang, Ming-Yue Li, George Gong Chen, Xing Zeng

Original Paper

miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma

Ruijing Lu, Ziliang Ji, Xiaoqing Li, Qingna Zhai, Chunjuan Zhao, Zhimao Jiang, Shiqiang Zhang, Liping Nie, Zhendong Yu

Original Paper

Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers

Hong In Yoon, Woong Sub Koom, Yong Bae Kim, Byung Soh Min, Kang Young Lee, Nam Kyu Kim, Sang Joon Shin, Joong Bae Ahn, Ki Chang Keum

Original Paper

Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML)

M. Philipp, J. Schwaab, C. T. Dietz, B. Hanfstein, L. Kalmanti, U. Munjal, M. Mossner, D. Nowak, W. Seifarth, W. K. Hofmann, A. Hochhaus, M. C. Müller, P. Erben

Original Paper

Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer

Chuanhao Tang, Hongjun Gao, Xiaoyan Li, Yi Liu, Jianjie Li, Haifeng Qin, Weixia Wang, Lili Qu, Juan An, Shaoxing Yang, Xiaoqing Liu

Original Paper

Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer

Jung Wook Huh, Woo Yong Lee, Yoon Ah Park, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Ho-Kyung Chun

Original Paper

Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer

Edward B. Garon, Heather R. Christofk, Wylie Hosmer, Carolyn D. Britten, Agnes Bahng, Matthew J. Crabtree, Candice Sun Hong, Naeimeh Kamranpour, Sharon Pitts, Fairooz Kabbinavar, Cecil Patel, Erika von Euw, Alexander Black, Evangelos D. Michelakis, Steven M. Dubinett, Dennis J. Slamon

Original Paper

Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status

Jinghui Wang, Yujie Dong, Yiran Cai, Lijuan Zhou, Shafei Wu, Guimei Liu, Dan Su, Xi Li, Na Qin, Jingying Nong, Hongyan Jia, Quan Zhang, Jing Mu, Xuan Zeng, Haiqing Zhang, Shucai Zhang, Zongde Zhang

Original Paper

Imbalance in redox status is associated with tumor aggressiveness and poor outcome in lung adenocarcinoma patients

Leonardo Lisbôa da Motta, Carolina B. Müller, Marco A. De Bastiani, Guilherme A. Behr, Fernanda S. França, Ricardo F. da Rocha, Juliane B. Minotto, Rosalva T. Meurer, Marilda C. Fernandes, Adriana Roehe, Melissa M. Markoski, Cristiano F. Andrade, Mauro A. A. Castro, Fábio Klamt

Original Paper

Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma

Li Kai, Zuopeng Wang, Wei Yao, Kuiran Dong, Xianmin Xiao

Original Paper

Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center

Dong Fang, Lei Zhang, Xuesong Li, Gengyan Xiong, Xiaopeng Chen, Wenke Han, Zhisong He, Liqun Zhou

Original Paper

Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: A possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?

Oliver Ristow, Carlos Gerngroß, Markus Schwaiger, Bettina Hohlweg-Majert, Melanie Ristow, Steffen Koerdt, Roswitha Schuster, Sven Otto, Christoph Pautke

Original Paper

High FDG uptake predicts poorer survival in locally advanced nonsmall cell lung cancer patients undergoing curative radiotherapy, independently of tumor size

Sukran Ulger, Nilgun Yilmaz Demirci, Fatma Nazan Eroglu, Huriye Hulya Cengiz, Mustafa Tunc, Ebru Tatci, Ulku Yilmaz, Eren Cetin, Emine Avci, Mustafa Cengiz

Original Paper

Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma

Toshiaki Tanaka, Toshihiko Torigoe, Yoshihiko Hirohashi, Eiji Sato, Ichiya Honma, Hiroshi Kitamura, Naoya Masumori, Taiji Tsukamoto, Noriyuki Sato

Original Paper

Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma

Bengt-Åke Andersson, Freddi Lewin, Jan Lundgren, Mats Nilsson, Lars-Erik Rutqvist, Sture Löfgren, Nongnit Laytragoon-Lewin

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.